Final/effective
Semaglutide injection shortage resolved
FDA's February 2025 order ends the Ozempic and Wegovy shortage. Compounding transition windows are now closing.
Updates
Source-linked updates on what changed, what did not change, and what to watch next.
Effective
WADA 2025 Prohibited List now in force
The updated list, effective January 1, 2025, keeps non-approved peptides such as BPC-157 in S0 and reminds athletes that sport rules differ from drug-approval rules.
Final/effective
Tirzepatide shortage resolved: what changed for compounders
FDA's December 2024 declaratory order ends the national shortage of Mounjaro and Zepbound. Here's what the status change does—and does not—mean.
Enforcement action recorded
FDA warning letter: retatrutide and sermorelin products are unapproved new drugs
The December 2024 Xcel Research warning letter shows how FDA treats 'research use only' labels when website claims indicate intended human use.
Final
FDA places BPC-157 in Category 2 significant safety risks
The September 2024 update to the 503A bulk list keeps BPC-157 off the lawful compounding list because of safety concerns.